explore -WSS

explore

author：Wikipedia 2025-09-30 14:59:18 - browse：279

Three boxes of Wegovy stands in a line — coverage from STAT — Steffen Trumpf/picture alliance/Getty Images

WASHINGTON — Novo Nordisk’s newly won permission to market the heart benefits of its obesity drug Wegovy could provide a backdoor way to expand access to the drug for people on Medicare, experts told STAT.

Currently, Medicare is prohibited by law from covering medications for obesity treatment alone. While companies that manufacture wildly popular anti-obesity medications and their allies haven’t been successful in lobbying Congress to change the law, the Food and Drug Administration’s move could give doctors an avenue to prescribe the medications to some Medicare patients.

Wegovy’s new label indicates that the drug can be used to reduce the risk of major heart complications for people who are overweight or obese and have existing heart disease, Novo said in a statement Friday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： To avoid data mishandling cases, universities eye AI and other tools

entertainment

WSS

Diversifying clinical trials isn't enough to close racial gaps: study

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Medical mystery: When a cough is not just a cough

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

For Medicare Advantage, Democrats want stronger protections around AI

Readout Newsletter: What happened with Sarepta's Duchenne data

focus

explore

hotspot

Walensky prepares to leave CDC — and Congress — behind

Robert F. Kennedy is pitching centrism on health, even on abortion

Anesthesiologist group: stop taking Ozempic before surgery

Senate panel to vote on hospitals, PBMs, prisoner care

Medical records are filled with copy

Telehealth options flood the market as retailers push virtual care

After affirmative action ruling, medical educators look to 'holistic review'

Telehealth options flood the market as retailers push virtual care

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout LOUD podcast: How biotech is using artificial intelligence

entertainment

Robert F. Kennedy is pitching centrism on health, even on abortion

Industry veterans launch new biotech VC with $310M

Gilead might be held responsible for not developing a drug

To avoid data mishandling cases, universities eye AI and other tools

Medical mystery: When a cough is not just a cough

KalVista pill reduced swelling 'attacks' caused by genetic disease

leisure time

entertainment

hotspot

knowledge